G laucoma is a progressive optic neuropathy characterized by structural optic nerve head changes and visual field loss. The leading cause of irreversible blindness worldwide, glaucoma affects 64.3 million people, and this is expected to increase to 111.8 million by 2040. 1 The global prevalence of open-angle glaucoma (OAG) between 40 and 80 years is estimated at 3.54% worldwide. 1, 2 Major risk factors for OAG include age and intraocular pressure (IOP). 3 Intraocular pressure is currently the only modifiable major risk factor for OAG development and progression. 4 Medical and surgical therapies have been successfully introduced that lower IOP by reducing aqueous production and increasing outflow; however, these therapies are not without adverse effects. Furthermore, it is not uncommon for the disease to progress despite successful IOP reduction. 5 Therefore demand continues for the discovery of novel therapeutic agents that offer patients protection from the onset and progression of glaucomatous visual loss.
During development pipelines, 90% of drug candidates fail at some point, leaving only 10% as a marketable product. 6 Failure late in clinical development results in greater amounts of time, money, and effort invested with little or no return. Drug repurposing is a process of finding new uses for drugs outside the scope of the original indication. 7 This benefits from reduced risk and costs because the drug candidates have either already been approved for clinical use or been through several stages of clinical development with known safety and pharmacokinetic profiles. 8 Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which is a rate-limiting enzyme necessary for the production of the intermediate product Lmevalonate in the biosynthetic pathway of cholesterol. 9 Statins are a relatively well tolerated class of cholesterol-lowering medication commonly prescribed in patients with dyslipidemia for the primary and secondary prevention of cerebrovascular and cardiovascular disease. Clinical and scientific evidence suggests that statins are capable of reducing the risk of cerebrovascular and cardiovascular disease independent of their effect on cholesterol levels. 10, 11 The so-called pleiotropic properties of statins such as inhibition of isoprenylation of RhoGTPase 12 and immunomodulation 13 have been proposed to protect retinal ganglion cells (RGCs) against glaucomatous damage. 14 Thus there has been increasing interest in the potential role of statins in glaucoma pathologic mechanisms and therapeutics. 15 The purpose of this literature review is to examine the current clinical and epidemiologic evidence investigating the strength and consistency of the association between clinical iovs.arvojournals.org j ISSN: 1552-5783
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METHODS
We followed the MOOSE guidelines 16 and registered our review at PROSPERO International Prospective Register of Systematic Reviews (http://www.crd.york.ac.uk/PROSPERO, registration no: CRD42015014875). This article adheres to the PRISMA statement 17 checklist for the preferred reporting of systematic reviews and meta-analysis.
Eligibility Criteria for Considering Studies for This Review
This systematic review focused on studies that investigated the association between statin use and glaucoma incidence or progression and the effect on IOP. Included studies were limited to primary research; however, they were not limited by design, sample size, participants, follow-up, or primary outcome measures.
Search Methods for Identifying Studies
Medline (1946-February week 3 2016) and Embase (1980-2016 week 8) were searched on 24 February, 2016 (Fig. 1) . The search strategy used subject headings in both databases: MeSH terms in Medline and Emtree terms in Embase (Appendix 1). PubMed and Google Scholar searches were also conducted using the search terms ''glaucoma'' and ''statins'' to pick up any articles that had not been added to Medline yet. The search strategies were limited to human studies and English language. Included studies were limited to published studies to the exclusion of editorials, commentaries, and article summaries. 
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Reference lists of articles were also interrogated for additional relevant papers. Abstracts were also included.
Study Selection
Two authors (REH and PM) screened all titles and abstracts generated from the searches to find studies that contained information on the topic of interest. Full articles were retrieved for detailed assessment by two authors, and papers that did not meet the inclusion criteria were excluded.
Data Collection
Each study was characterized by extracting methodological details onto a predesigned form by two independent reviewers. 18 Relevant outcomes and results were extracted into another form and were screened for comparability. When there were inconsistencies between reviewers' opinions, there were further discussions until consensus was reached. In studies in which more than one estimate of effect was presented, agreement was reached about the most appropriate ''adjusted'' estimate to include. Attempts were made to contact authors by e-mail when papers presented insufficient data.
Risk of Bias Assessment
Risk of bias in the nonrandomized observational studies was assessed using Newcastle-Ottawa Quality Assessment Scale (NOS) for cohort and case-control studies as outlined in The Cochrane Handbook of Systematic Reviews. 18 The NOS includes a star system in which a study is judged on three domains (Appendix 2); representativeness of study group selection (four items), comparability of groups (two items), and ascertainment of either the exposure or outcome in casecontrol studies or cohort studies (three items). Studies score a star for each item addressed with a score ranging from 0 to 9. Those studies scoring greater than 7 were distinguished from scores 7 as having a lower risk of bias. The cutoff of 7 was used as it had been adopted by a previous review. 19 Two independent reviewers repeated this process, and inconsistencies were discussed until consensus was reached. When insufficient information was available to ascertain the NOS score, attempts were made to contact authors for further details.
Data Synthesis and Analysis
Statistical analysis and meta-analysis were performed using RevMan 5.3 software (The Cochrane Collaboration, Copenhagen, Denmark). We combined the results of different study designs in the meta-analysis because we used the ''rare disease assumption'' that odds ratios (OR) and risk ratios can be considered equivalent when the disease has a prevalence less than 5%. 20, 21 The v 2 test of between-study heterogeneity was used to test the null hypothesis that the underlying treatment effect of statins is identical in all studies. The test statistic, Q, follows a v 2 distribution with the degrees of freedom equal to the number of studies minus 1. The I 2 statistic measured the degree of inconsistency in the observed treatment effect of statins by measuring the percentage of total variation across the studies that is due to heterogeneity rather than chance. Forest plots were used to graphically represent the investigation of heterogeneity. Within the forest plots, estimates were stratified into subgroups on the basis of length of exposure to statins ( 2 and >2 years) because the primary studies made these stratifications. Overall effect size was then determined for each of the subgroups. A further meta-analysis was performed on estimates that were not subgrouped by length of exposure to statins. We used the most conservative of the two effects models, random effects, to estimate the pooled effect size. This takes into account extra variations when assuming that the studies are estimating different underlying treatment effects. Publication bias was checked for using funnel plots. Sensitivity analysis was performed to examine the impact of poor-quality studies upon the meta-analysis. For the purposes of the description of the results, study outcomes were classified into the three domains relevant to glaucoma: incidence, progression, and IOP.
RESULTS
The initial searches identified 307 records after the removal of duplicates (Fig. 1) . Following screening of these 307 records, 293 were excluded due to being either irrelevant or nonepidemiologic studies. Full texts of 14 potentially relevant manuscripts were retrieved. Three were excluded due to being editorials, commentaries, or summaries of other included studies. The remaining 11 studies explored the association between primary OAG and statin use and were included. Of these 11 studies, 9 were full studies and 2 were abstracts. No randomized controlled trials were retrieved. Four studies investigated glaucoma incidence, one study investigated both glaucoma incidence and progression, and five other studies investigated glaucoma progression. The effect of statin therapy on IOP was reported in three studies. The publication dates for all the studies ranged between 2004 and 2015.
Descriptions of populations, sample sizes, and outcome measures are outlined in Table 1 and the design for each study is defined in Table 2 . The definition of the glaucoma-related outcome measure, the method of ascertainment of statin exposure, and the estimated effects of statins on incidence, progression, and IOP for each included study are presented in Tables 3 to 5 , respectively.
Risk of Bias Assessment
Using the NOS, six cohort studies were judged to score ‡8 and the remaining two cohort studies were judged to score 7 in quality ( Table 6 ). The lowest-scoring cohort studies were from the two gray literature abstracts with scores of 5 and 0 out of 9. One case-control study was judged to score ‡8 on the NOS, and the other two were judged to have scored 7 (Table 7) .
Statin Use and Incidence of Glaucoma
The association between statin use and incidence of glaucoma was examined in five studies: two nested case-control studies, one case-control study, one retrospective cohort study, and one prospective cohort study. The outcomes for each study were stratified by the length of exposure to statins as per the primary studies and were then outlined in forest plots (Figs. 2,  3) . A further meta-analysis was performed on outcomes reported from studies that did not stratify by the length of exposure (Fig. 4) . Overall estimates for incidence of glaucoma were presented in forest plots. For exposure to statins for 2 years, overall estimated OR was 0.96 (95%CI [confidence interval] 0.94, 0.99) and for >2 years, overall estimate OR was 0.70 (95%CI 0.46, 1.06). Meta-analysis of outcomes that were not stratified by length of exposure did not show a statistically significant reduction in the incidence of OAG (OR 0.94, 95%CI 0.83, 1.06).
Among studies evaluating the short-term use of statins, McGwin et al., 22 Owen et al., 23 and Stein et al. 24 used diagnostic read codes to define glaucoma incidence, whereas Marcus et al. 25 used a clinical diagnosis. McGwin et al. 22 were 23 did not find a significant association between short-term statin use and glaucoma incidence when adjusted for a socioeconomic index, comorbidities, and other medications taken (OR 0.98, 95%CI 0.89, 1.08). Marcus et al. 25 were unable to demonstrate a statistically significant protective effect of cumulative statin use for less than 2 years (hazard ratio
[HR] 0.89, 95%CI 0.41, 1.94). However, Stein et al. 24 found statistically significant protective effects of statin use for 1 year using two parameters of glaucoma incidence: OAG onset from no previous diagnosis (HR 0.960, 95%CI 0.933, 0.988) and incidence of medical treatment for OAG (HR 0.950, 95%CI 0.924, 0.976).
Regarding the long-term use of statins, three studies reported an association with reduced OAG incidence. McGwin et al. 22 and Stein et al. 24 used diagnostic read codes to define 24 found statistically significant protective effects of statin use for 2 years using OAG onset from no previous diagnosis (HR 0.922, 95%CI 0.870, 0.976) and incidence of medical treatment for OAG (HR 0.902, 95%CI 0.854, 0.953).
Our meta-analysis suggests that statin therapy for 2 years confers a 4% reduction in the incidence of OAG (Fig. 2) while statin therapy for >2 years did not confer a statistically significant reduction in the incidence of OAG (Fig. 3) . Statin use not stratified by length of exposure to statins also did not confer a statistically significant reduction in the incidence of OAG (Fig. 4) . 
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Publication Bias
Funnel plots that plot the OR on the log scale (x-axis) against the standard error of the log odds (y-axis) were used to examine publication bias and the possibility of type 1 error. In Figure 5 there is no evidence of asymmetry in the funnel plot examining short-term statin use, and consequently no publication bias is apparent in these studies. Funnel plots were not conducted for longer-term statin use and statin use not stratified by length of exposure because too few studies were available.
Sensitivity Analysis
In the sensitivity analysis, the overall heterogeneity and effect size was calculated following exclusion of the studies 22 was removed from the analysis there was no change in the pooled OR comparing statin use for 2 years versus controls (OR 0.96, 95%CI 0.94, 0.99). There was a change in the pooled OR comparing statin use for >2 years versus controls when McGwin et al. 22 was removed but it did not affect the statistical significance of the result (OR 0.71, 95%CI 0.37, 1.38). When McGwin et al. 22 and Chen et al. 26 were removed from the analysis of pooled ORs that were not stratified by length of exposure, there was no effect on the statistical significance of the result (OR 0.77, 95%CI 0.44, 1.35).
Statin Use and Progression of Glaucoma
The association between statin use and progression of glaucoma was reported in four full studies and two abstracts (Table 4) . Among these there were five retrospective cohort studies and one prospective cohort study. There were different definitions of glaucoma progression across all of the studies, which meant that meta-analysis could not be performed. There were conflicting results across studies regarding association between statin use and progression. De and coauthors (De M, et al. IOVS 2006;47:ARVO E-Abstract 3398) defined progression as the average change in mean deviation of the visual field test per year. They found no statistically significant difference in the average change in mean deviation per year or pattern standard deviation per year between controls and users of statin for greater than 23 months. De Castro et al. 27 defined OAG progression using various clinical parameters. They found no statistical difference among the number of patients who progressed to ''outside normal limits'' on glaucoma hemifield visual field test in the statin group compared to controls. However, they did find significant differences in the progression of multiple confocal scanning laser ophthalmoscopy parameters per year including rim volume, retinal nerve fiber layer cross-sectional area, and mean global retinal nerve fiber layer thickness, which favored the statins group when adjusted for multiple systemic and ocular factors. An abstract by Tong 28 in 2008 found that univariate analysis of statin use was correlated with stable disease. However, descriptions of the study population, method of assessment, and adjustment for confounders were not reported. The study scored 0 on NOS. Iskedjian et al. 29 used read code data for the addition of adjunctive medical therapy in those taking prostaglandin analogues for glaucoma as a surrogate marker for progression. They found that the proportion of patients initiating adjunctive medical therapy for glaucoma in the statin group was less than in those not taking any systemic medication, although this did not reach statistical significance. In a prospective cohort study of normal-tension glaucoma, Leung et al. 30 found that the proportion of patients who took statins in the group that remained stable was significantly higher than the proportion of patients who took statins in the group who progressed. A logistic regression model adjusting for a history of disc hemorrhages, cerebrovascular disease, and age at baseline showed that simvastatin use conferred a significant protective effect against visual field progression. In a retrospective cohort study, Stein et al. 24 used read code changes from ''suspect OAG to OAG diagnosis'' and ''surgical treatment for OAG'' as proxies for progression. Those who took statins for 1 or 2 years had decreased hazard of progressing to OAG from OAG suspect compared to those who did not receive statins (Table 4 ). However, hazard of an individual with OAG later requiring laser or incisional glaucoma surgery was not significantly reduced with statin exposure. HbA1c, Glycosylated Haemoglobin.
* A star awarded to the study for that component of the Newcastle Ottawa Scale.
Statin Use and IOP
The association between statin use and IOP was presented in three studies (Table 5 ). Leung et al. 30 and Marcus et al. 25 reported no significant changes in IOP associated with statin use. Khawaja et al. 31 reported a significant reduction in IOP among statin users compared to non-statin users when adjusted for age and sex (b À0.31, 95%CI À0.51, À0.12 P ¼ 0.002). However, when adjusted for beta-blocker therapy, the association was no longer significant.
DISCUSSION
To date this is the only systematic review that evaluates the association between statin use and glaucoma. Our search yielded no randomized controlled trials but 11 observational and case-control studies with sample sizes ranging from 76 to over 500,000 participants. Meta-analysis of the effect of shortterm statin therapy on the incidence of glaucoma demonstrated a 4% reduced risk of glaucoma; however, long-term therapy did not demonstrate a statistically significant effect. Similarly, we did not find any significant association between statin use and incidence of glaucoma when outcomes were not stratified according to length of exposure to statin therapy. A previous meta-analysis by Macedo et al. 19 evaluating the unintended effects of statins identified only three studies investigating the association with glaucoma and statin use, whereas we have identified a more complete set of evidence. Furthermore those authors did not report on short-versus long-term exposure to statin therapy. Macedo et al. 19 found an overall pooled OR estimate of 0.86 (95%CI 0.69, 1.08).
Read codes are a system by which diagnostic codes are allocated to patients within databases based on the clinical diagnosis as entered in the system, but not necessarily independently validated. The use of read code to classify glaucoma incidence and progression in several studies [22] [23] [24] 26, 29 poses the risk of misclassification bias. Caution must therefore be employed when interpreting these studies. By far the largest identified study was conducted by Stein et al. 24 with a study population of over 500,000 individuals. The sample was identified by the individuals' hyperlipidemia status. Hence the generalizability of these results may be limited to the 22 (second from top): Upper limit of 95%CI (1.38) is not exactly equivalent to upper limit of 95%CI in Table 3 (1.39) due to rounding in meta-analysis software.
population with hyperlipidemia. As the largest study identified, the study by Stein et al. 24 carries most weight; however, it is retrospective and uses read code data to define glaucoma, and therefore the quality of evidence from this study is relatively poor and the results need to be interpreted with caution.
The use of nonstatin cholesterol-lowering drugs (NSCLDs), a possible confounding factor, was reported by McGwin et al., 22 Stein et al., 24 Marcus et al., 25 and Chen et al. 26 McGwin et al. 22 found that NSCLD use for less than 12 months was associated with reduced incidence of OAG (OR 0.38, 95%CI 0.18, 0.79), and Stein et al. 24 found that persons who took NSCLD for 2 years had a 14% decreased risk of being prescribed a glaucoma medication (adjusted HR 0.862, 95%CI 0.785, 0.946). In contrast, Marcus et al. 25 and Chen et al. 26 did not demonstrate statistically significant protective effects of NSCLDs in glaucoma. In these studies NSCLDs were defined as a heterogeneous group of medications encompassing various classes of drugs. Certain classes of NSCLDs such as peroxisome proliferator-activated receptor alpha (PPARa) agonists (fibrates) have been shown to exhibit immunomodulatory pleiotropic effects independent of their lipid-lowering properties 32 and have been shown to work synergistically with statins. [33] [34] [35] Statins may induce IOP lowering by increasing aqueous outflow. 36 The confounding effect of systemic betablocker therapy on the effect of statins on IOP lowering was reported by Khawaja et al. 31 They reported that the observed IOP-lowering effect of statins was no longer significant following adjustment for systemic beta-blocker therapy. Thus FIGURE 3. Forest plot of incidence of glaucoma and statin use >2 years versus control. Marcus et al., 25 upper limit of 95%CI (0.92) is not exactly equivalent to upper limit of 95%CI in Table 3 (0.94) due to rounding in meta-analysis software. FIGURE 4. Forest plot of incidence of glaucoma and statin use from outcomes not stratified by length of exposure. Marcus et al., 25 upper limit of 95%CI (0.94) is not exactly equivalent to upper limit of 95%CI in Table 3 (0.96) due to rounding in meta-analysis software. Owen et al., 30 upper limit of 95%CI (1.07) is not exactly equivalent to upper limit of 95%CI in Table 3 (1.06) due to rounding in meta-analysis software. the confounding effects of NSCLDs and systemic beta-blockers should be considered in the design and analysis of future interventional studies.
From our study we cannot rule out confounding by indication, 37 and we must ask if it is the hyperlipidemia that might be protective or the statin use. A study by NewmanCasey et al. 38 showed that hyperlipidemia was associated with a decreased risk in developing OAG; however, they could not determine whether it was the treatment for hyperlipidemia that reduced the risk or the hyperlipidemia itself. A study by Wang et al. 39 showed that dyslipidemia was not significantly associated with the prevalence of glaucoma; however, they showed that dyslipidemia was associated with higher IOP and beta zone of parapapillary atrophy in a Chinese population. Chen et al. 26 demonstrated that higher dosages of statins are associated with increased risk of OAG (OR 1.24, 95%CI 1.03, 1.49). They proposed that higher dosages of statins were an indication of poorer lipid control that was the cause of the increased risk of OAG.
There were a number of strengths in this review. The sensitivity of our search strategy was maximized by restricting the exclusion criteria during the screening stage. However, the observational studies included are susceptible to various systematic biases depending on whether they are case-control or cohort designs. Case-control studies are generally prone to selection bias and require strict case definition to prevent misclassification bias. Cohort studies are considered methodologically superior to case-control studies; however, they are expensive and must be well conducted to prevent loss to follow-up. Cross-sectional studies are useful to estimate prevalence but are of limited value when investigating incidence. For each study we addressed the risk of bias using a range of tools recommended in The Cochrane Handbook of Systematic Reviews. 18 In addition, the comprehensive approach adopted to ascertain confounding factors in each study added to the strength of the review. Potential confounding factors identified and controlled for in each study are outlined in Table 1 .
Weaknesses of the study include the exclusion of literature in languages other than English. To reach a wider audience, significant results tend to be published in English; therefore a degree of publication bias may be introduced by language restriction. Our investigation of publication bias did not reveal type 1 error in the results of studies investigating the shortterm effects of statin use and incidence of glaucoma. A limitation in our study is that we had too few studies to investigate possible publication bias in studies investigating long-term statin exposure and those not stratified by length of exposure to statins. Although abstracts were identified and included, a formal search of gray literature databases was not performed, which may have contributed to publication bias. Another limitation in the reporting of our results is defining glaucoma as ''commencing glaucoma medications'' because some people may have ocular hypertension and not glaucoma. However, we addressed this by not including these estimates in the meta-analysis.
In conclusion, the results of our meta-analysis provide evidence for the association between the short-term use of statin therapy and a reduced incidence of glaucoma. However, the observational design of the studies in the meta-analysis limits the ability to make inferences about whether or not exposure to statins causes reduced incidence of glaucoma. There was inconsistent evidence for the IOP-lowering effect of statins and the effect of statins on the progression of OAG. The associations observed in this review warrant a prospective interventional randomized controlled study with short-and long-term follow-up to provide further insight into the role of statin therapy in the prevention of onset or progression of glaucoma and its effects on IOP.
